Salute e Benessere

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of…

This Phase Ib study builds on an earlier collaboration between TFS and Oncomatryx during a Phase I trial evaluating OMTX705 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. The promising results from that study laid the foundation for this next phase of development and exemplified the consistent performance, deep therapeutic expertise, and oncology specialization that Oncomatryx values in its continued partnership with TFS. This Phase Ib study...

Essential Pharma strengthens management team with appointment of Duncan Ferguson…

Egham, UK – 6th May 2025– Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Duncan Ferguson as Vice President, Commercial.Duncan joins Essential today and will support the continued growth of the Company's portfolio of medicines for small, underserved or rare disease populations. He will join the Leadership Team and drive the commercial strategy of the...

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production…

Exercised options total USD 143.6 millionSecures manufacturing and supply of freeze-dried JYNNEOS ®to the U.S. in 2026COPENHAGEN, Denmark, May 6, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 143.6 million under the existing...

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain…

Lundbeck expects that Gefion will contribute to advancing research by providing AI-driven insights into molecule discovery and drug optimization in the development of therapies. By exploring innovative avenues for molecule discovery, Lundbeck aims to identify novel and better medicines for known drug targets as well as unlocking emerging drug targets to deliver new treatment options for people living with brain disorders, including rare and specialist-treated neurological conditions. Lundbeck...

Implantica announces 15th RefluxStop™ Center in Spain

Dra. Moreno Gijón says, "I have been seeking a new surgical option to treat GERD for years. So many patients have lost hope of managing their symptoms after suboptimal outcomes from current treatments. Many others with complicated conditions are waiting to be treated as they are not even eligible for typical anti-reflux surgical treatment options and for whom medication isn't effective. RefluxStop™ finally gives all GERD patients a chance to experience the benefits of a safe and durable…

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

PARIS, FRANCE, 06 May 2025– Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen's Chief Executive Officer (CEO), David Loew. “We are very pleased to welcome Laura to Ipsen as our EVP for Strategy & Transformation. I have observed Laura's involvement in...

Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief

The Mexican allowance adds to previously granted counterpart patents in the United States, Russia, and Ukraine, and complements a growing portfolio of pending applications across various global jurisdictions. This development positions Innocan for early and strategic access to Latin American markets. The Mexican allowance adds to previously granted counterpart patents inthe United States,Russia, andUkraine, and complements a growing portfolio of pending applications across various...

Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25

Interim financial results, H1 2024/251 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin 1held steady at 27%. Reported revenue in DKK grew 5%, impacted by the Skin Care divestment.Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.Growth in...

Roche introduces innovative Elecsys PRO-C3 test to improve precision in…

Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide 1 The test delivers results in just 18 minutes on Roche's cobas analysers, providing a fast and reliable diagnostic method.The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging...

Philips delivers on Q1 results, with ongoing order intake growth

Q1 2025 Group performanceGroup sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips...

Intravenous Immunoglobulin (IVIG) Market Forecast to Surge During the Forecast…

Key Takeaways from the IVIG Market Report Key Takeaways from the IVIG Market Report Discover which therapies are expected to grab the IVIG market share @ Intravenous Immunoglobulin Market Report IVIG Market Dynamics The intravenous immunoglobulin market has seen significant growth over the last few years, driven by a combination of factors, including theincreasing incidence of autoimmune and inflammatory disorders, therising prevalence of immunodeficiencies, and...

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY.A live webcast of the fireside chat can be accessedhere, and will also be available on...

uniQure to Announce First Quarter 2025 Financial Results

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is...

Digital Wound Management Devices Market to Reach USD 3,594.49 million By 2032…

Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/digital-wound-management-devices-market Browse the report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/digital-wound-management-devices-market Key Growth Determinants Rising Prevalence of Chronic WoundsThe increasing global incidence of chronic conditions such as diabetes, obesity, and vascular diseases...

INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral…

The landscape still shows that the majority of clinical and preclinical compounds under investigation are targeting the viruses where infection can lead to outbreaks of COVID-19 and influenza. Other indications where limited clinical and/or preclinical development work is underway include Mpox, Dengue, Ebola, and Lassa fever, among others. However, there are several viral families of pandemic potential with no compounds in clinical or preclinical development at this time leaving the world at…

IBA – ACQUISITION OF OWN SHARES

Immediate Release – May 5 th, 2025 Louvain-la-Neuve, Belgium, May 5 th, 2025 -In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24 th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of...

AI Healthcare Boom Gains Speed as Regulators and Innovators Align

VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of…

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic…

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on LusvertikimabLusvertikimab well tolerated over the 24-week additional treatment period.Oral presentation at DDW 2025 of clinical data from the anti-IL-7R mAb Lusvertikimab open-label extension of the phase 2 CoTikiS study in ulcerative colitis. 1 ,2 Full clinical data package for study demonstrates potential of a first-in-class monotherapy with a novel mechanism of...

AB Science will present new data from masitinib clinical program in ALS in two…

PRESS RELEASEAB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETINGMASITINIB REDUCES SERUM NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS, SUGGESTING THAT IT HAS DISEASE-MODIFYING POTENTIALCLINICAL BENEFIT, INCLUDING CAFS AND SURVIVAL, IS GREATEST IN A SUBGROUP OF ALS PATIENTS THAT SERVES AS THE BASIS FOR THE RECENTLY AUTHORIZED PHASE 3 CONFIRMATORY STUDYParis, May 5, 2025, 6pm CETAB...

Coloplast A/S CEO Kristian Villumsen steps down as of today

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy period, the Board of Directors has decided to initiate the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. As a result, President and CEO, Kristian Villumsen, steps down as of today.To ensure continuity, the Chair of the Board...

Digital Twins in Healthcare Market worth US$59.94 billion by 2030 with 68.0%…

Browse in-depth TOC on "Digital Twins in Healthcare Market" Browse in-depth TOC on "Digital Twins in Healthcare Market" 226 - Tables 55 - Figures 254 - Pages By Based on type,the digital twins in healthcare market is segmented into process twins, system twins, whole body twins, and body part twins. The process twins segment accounted for the largest share of the market in 2024. The key factors contributing to the growth of this market include advancements in technology,...

Fire-resistant Lubricants Market worth $2.73 billion by 2030 - Exclusive Report…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=239428812 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=239428812 Fire-resistant lubricants are in high demand because of their key function in enhancing operational safety, lowering the risk of fire, and ensuring equipment reliability in high-risk industrial operations. Industries such as metal processing, mining, power generation, aerospace, construction, and marine...

Holter ECG Market worth US$0.76 billion by 2030 with 6.5% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54808904 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54808904 Browse in-depth TOC on "Holter ECG Market" 421 - Tables 57 - Figures 408 - Pages By Based on product,During the forecast period, the wired Holter ECG monitors segment is expected to experience significant growth. The Holter ECG market is categorized into wired Holter ECG monitors, wireless...

Skin Analyzer Market to Reach USD 402.8 Million by 2032, Growing at a CAGR of…

Browse in-depth scope of Skin Analyzer Market Report: Browse in-depth scope of Skin Analyzer Market Report: 250 – Pages 94 – Tables 30 – Figures For more comprehensive insights, download the FREE report sample:https://www.meticulousresearch.com/download-sample-report/cp_id=6159 Advanced Diagnostics and AI Integration Propel Market Growth The growth of the skin analyzer market is largely fueled by growing consumer awareness of skin health, advancements in non-invasive...

Altri Comunicati